Zilurgisertib (INCB000928, NBU-928) is a potent, selective and orally available wild-type and mutant ALK2 (R206H).
INCB000928 significantly reduces the production of hepcidin in human liver cells, primary hepatocytes and rodent models of anemia.
INCB000928 has shown efficacy in preventing injury-induced heterotopic ossification in a human FOP mouse model, offering a promising path to clinical proof-of-efficacy studies and potential benefits to patients with hepcidin-induced anemia and FOP
